

Advancing Precision Psychiatry with AI and Genomics for Personalized Treatment

Dhoha Bastaki^{*}

Department of Psychiatry, Elazıg Fethi Sekin City Hospital, Elazıg, Turkey

DESCRIPTION

Precision psychiatry is an innovative and rapidly evolving approach that integrates Artificial Intelligence (AI) and genomics to develop highly personalized treatments for mental health disorders. Unlike traditional psychiatric practices, which often follow standardized treatment protocols based on populationwide data, precision psychiatry tailors interventions according to an individual's unique genetic, neurobiological and psychological characteristics. This paradigm shift in psychiatric care aims to improve treatment efficacy, reduce adverse effects and enhance overall patient outcomes by leveraging cutting-edge advancements in genomics, AI and computational neuroscience [1]. Genomics plays a pivotal role in precision psychiatry by identifying genetic variations associated with various psychiatric conditions, including schizophrenia, bipolar disorder and major depressive disorder. Genome-Wide Association Studies (GWAS) and Polygenic Risk Scores (PRS) have revolutionized the field by enabling clinicians to assess an individual's genetic susceptibility mental illnesses. GWAS identify specific genetic loci to associated with psychiatric disorders, while PRS aggregate multiple genetic risk variants to provide a quantitative measure of an individual's predisposition to a particular condition. These genomic insights allow for early identification of at-risk individuals and facilitate preventive interventions tailored to their genetic profiles [2].

In addition to genetic predisposition, epigenetic modifications influenced by environmental factors such as stress, trauma and substance use further contribute to the complexity of psychiatric disorders. Epigenetics refers to reversible chemical changes in DNA and histone proteins that regulate gene expression without altering the underlying genetic code. Studies have demonstrated that adverse childhood experiences, chronic stress and exposure to toxins can lead to epigenetic modifications that influence brain function and behavior [3]. By integrating genomic and epigenetic data, researchers can gain a more comprehensive understanding of the biological mechanisms underlying mental health conditions, ultimately paving the way for more precise

and effective therapeutic strategies. Artificial Intelligence significantly enhances precision psychiatry by improving diagnostic accuracy, predicting treatment outcomes and optimizing therapeutic interventions. Machine Learning (ML) algorithms process vast datasets, including neuroimaging scans, electronic health records and behavioral assessments, to detect biomarkers associated with psychiatric disorders [4]. These AIdriven analytical techniques facilitate early and accurate diagnosis, reducing the likelihood of misdiagnosis and enabling timely intervention. Furthermore, Natural Language Processing (NLP) tools analyze speech and text patterns to identify linguistic markers indicative of mental health conditions such as depression, anxiety and schizophrenia. By evaluating subtle changes in tone, syntax and word choice, NLP algorithms can detect early warning signs of psychiatric disorders, allowing for proactive intervention and personalized care [5].

AI-powered imaging techniques further contribute to precision psychiatry by enhancing the detection of neurobiological abnormalities associated with mental illnesses. Advanced neuroimaging modalities, such as functional Magnetic Resonance Imaging (fMRI) and Positron Emission Tomography (PET), provide insights into brain structure and function. Machine learning models trained on neuroimaging data can identify patterns of connectivity, volumetric changes and metabolic alterations linked to psychiatric disorders [6]. These findings help clinicians develop targeted treatment plans by identifying neurobiological markers that correlate with specific symptoms and disease trajectories. Personalized treatment strategies in precision psychiatry leverage pharmacogenomics to optimize medication selection based on an individual's genetic profile. Pharmacogenomics examines how genetic variations influence an individual's response to medications, thereby reducing the trial-and-error approach commonly associated with psychiatric drug prescriptions [7]. Variations in genes encoding drug-metabolizing enzymes, such as CYP2D6 and CYP2C19, affect the metabolism and efficacy of antidepressants, antipsychotics and mood stabilizers. For example, individuals with specific CYP2D6 variants may metabolize certain

Correspondence to: Dhoha Bastaki, Department of Psychiatry, Elazıg Fethi Sekin City Hospital, Elazıg, Turkey, E-mail: dhoha@bastaki.com

Received: 01-Jan-2025, Manuscript No. JOP-25-28575; Editor assigned: 03-Jan-2025, PreQC No. JOP-25-28575 (PQ); Reviewed: 17-Jan-2025, QC No. JOP-25-28575; Revised: 23-Jan-2025, Manuscript No. JOP-25-28575 (R); Published: 31-Jan-2025, DOI: 10.35248/2167-0358.25.28.733

Citation: Bastaki D (2025). Advancing Precision Psychiatry with AI and Genomics for Personalized Treatment. J Psychiatry. 28:733.

Copyright: © 2025 Bastaki D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

antidepressants too quickly or too slowly, leading to suboptimal therapeutic effects or increased risk of adverse reactions. By incorporating pharmacogenomic testing into clinical practice, psychiatrists can prescribe medications that are more likely to be effective and well-tolerated, enhancing treatment adherence and patient satisfaction [8].

Beyond pharmacogenomics, AI-driven digital mental health platforms are transforming psychiatric care by delivering personalized therapeutic interventions. Mobile applications, chatbots and virtual reality-based therapies use AI algorithms to tailor Cognitive Behavioral Therapy (CBT), mindfulness training and exposure therapy to an individual's unique needs. These platforms continuously adapt treatment strategies based on user responses, engagement levels and real-time feedback, ensuring a dynamic and personalized approach to mental health care [9]. Virtual reality exposure therapy, for instance, allows individuals with Post Traumatic Stress Disorder (PTSD) or phobias to undergo controlled exposure to triggering stimuli in a safe and monitored environment, facilitating gradual desensitization and symptom reduction. Despite its transformative potential, precision psychiatry faces several challenges that must be addressed to ensure its successful integration into clinical practice. Data privacy and security concerns are paramount, as psychiatric and genomic data are highly sensitive and require stringent safeguards to prevent unauthorized access and misuse. Ethical considerations surrounding AI-driven decision-making also pose challenges, as biases inherent in training datasets can lead to disparities in diagnosis and treatment recommendations. Ensuring the transparency, fairness and accountability of AI algorithms is critical to mitigating these risks and promoting equitable mental health care [10].

REFERENCES

1. Zimmerman M, Morgan TA, Stanton K. The severity of psychiatric disorders. World Psychiatry 2018;17(3):258-275.

OPEN ACCESS Freely available online

- Meerwijk EL, Tamang SR, Finlay AK, Ilgen MA, Reeves RM, Harris AH. Suicide theory-guided natural language processing of clinical progress notes to improve prediction of veteran suicide risk: protocol for a mixed-method study. BMJ open. 2022;12(8):e065088.
- Kosowan L, Singer A, Zulkernine F, Zafari H, Nesca M, Muthumuni D. Pan-Canadian Electronic Medical Record Diagnostic and Unstructured Text Data for Capturing PTSD: Retrospective Observational Study. JMIR Med Inform. 2022;10(12):e41312.
- Horigome T, Hino K, Toyoshiba H, Shindo N, Funaki K, Eguchi Y, et al. Identifying neurocognitive disorder using vector representation of free conversation. Sci Rep. 2022;12(1):12461.
- Cox DJ, Garcia-Romeu A, Johnson MW. Predicting changes in substance use following psychedelic experiences: Natural language processing of psychedelic session narratives. Am J Drug Alcohol Abuse. 2021;47(4):444-54.
- 6. Kizilay E, Arslan B, Verim B, Demirlek C, Demir M, Cesim E, et al. Automated linguistic analysis in youth at clinical high risk for psychosis. Schizophr Res. 2024;274:121-128.
- Arslan B, Kizilay E, Verim B, Demirlek C, Dokuyan Y, Turan YE, et al. Automated linguistic analysis in speech samples of Turkishspeaking patients with schizophrenia-spectrum disorders. Schizophr Res. 2024;267:65-71.
- Çabuk T, Sevim N, Mutlu E, Yağcıoğlu AE, Koç A, Toulopoulou T. Natural language processing for defining linguistic features in schizophrenia: A sample from Turkish speakers. Schizophr Res. 2024;266:183-189.
- Tsui FR, Shi L, Ruiz V, Ryan ND, Biernesser C, Iyengar S, et al. Natural language processing and machine learning of electronic health records for prediction of first-time suicide attempts. JAMIA Open. 2021;4(1):ooab011.
- Lim SR, Ng QX, Xin X, Lim YL, Boon ES, Liew TM. Public discourse surrounding suicide during the COVID-19 pandemic: An unsupervised machine learning analysis of twitter posts over a one-year period. Int J Environ Res Public Health. 2022;19(21):13834.